Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

September 29, 2026

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress ↗

Performance

52-Week Range 34.3% below 52-week high

62.75

34.6152W Low 95.4952W High

1 Week 3.1% below 1-week high

59.201W Low 64.761W High

Arrowhead Pharmaceuticals, Inc. - Common Stock (ARWR) traded between $34.61 and $95.49 over the past 52 weeks and last traded at $62.75, 34.3% below its 52-week high. Over the past week it ranged between $59.20 and $64.76.

Past 12 Months

+0.6%

-24.3%

-15.3%

-1.6%

-7.4%

+73.1%

1W +$0.40

1M -$20.10

3M -$11.36

6M -$1.04

YTD -$5.04

1Y +$26.50

ARWR was +73.1% over the past year, -1.6% over six months, -7.4% year to date, +0.6% in the last week.

12 Months vs Market

ARWR

+73.1%

DIA

+12.0%

SPY

+17.4%

QQQ

+24.8%

IWM

+14.1%

Over the past 12 months ARWR returned +73.1% versus DIA (Dow) +12.0%, SPY (S&P 500) +17.4%, QQQ (Nasdaq 100) +24.8% and IWM (Russell 2000) +14.1%.

Volume & Liquidity

2.1M

2.4M

1.9M

2.0M

YTD

2.3M

ARWR's 3-month average daily volume is 1.9M.

More News

September 18, 2026

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Flashes Bull Flag Breakout Setup with Top-Tier Technical Strength ↗

August 26, 2026

Via Chartmill

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands ↗

September 18, 2026

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

September 15, 2026

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million ↗

September 06, 2026

Via The Motley Fool

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

September 03, 2026

Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials ↗

August 31, 2026

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

August 30, 2026

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

August 24, 2026

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

August 17, 2026

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗

August 14, 2026

Via The Motley Fool

Arrowhead Pharmaceuticals Q3 Earnings Call Highlights ↗

August 04, 2026

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

August 04, 2026

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

August 04, 2026

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

August 03, 2026

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

July 27, 2026

Top movers analysis in the middle of the day on 2026-07-22: top gainers and losers in today's session. ↗

July 22, 2026

Via Chartmill

Gapping stocks in Wednesday's session ↗

July 22, 2026

Via Chartmill

These stocks are moving in today's pre-market session ↗

July 22, 2026

Via Chartmill

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

July 22, 2026

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

July 21, 2026

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

June 22, 2026

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

June 18, 2026